Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.03.2021 | Case report

Canagliflozin/empagliflozin

Bladder cancer: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Garcia M, et al. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database. Journal of Clinical Pharmacology 61: 187-192, No. 2, Feb 2021. Available from: URL: http://doi.org/10.1002/jcph.1722 Garcia M, et al. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database. Journal of Clinical Pharmacology 61: 187-192, No. 2, Feb 2021. Available from: URL: http://​doi.​org/​10.​1002/​jcph.​1722
Metadaten
Titel
Canagliflozin/empagliflozin
Bladder cancer: case report
Publikationsdatum
01.03.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-92670-0

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Unithiol

Case report

Multiple drugs